Clinical TrialJul 2, 2026, 07:32 AM
BridgeBio's Acoramidis Shows Early, Sustained Kidney Protection in ATTR-CM
AI Summary
BridgeBio Pharma announced new analyses published in Circulation: Heart Failure, demonstrating that acoramidis provides early and sustained kidney-protective activity in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM). The post-hoc analyses of Phase 2 and Phase 3 ATTRibute-CM trial data showed that acoramidis initiation was associated with a rapid, reversible eGFR dip and a significant reduction in urinary albumin to creatinine ratio (UACR), resembling the effects of drugs acting directly on the kidney. These findings suggest a direct kidney mechanism and potential for improved long-term survival and reduced cardiovascular hospitalizations in ATTR-CM patients.
Key Highlights
- Acoramidis showed a placebo-corrected 15.5% reduction in UACR by Day 28 (P<0.05).
- Sustained, improved chronic eGFR slope of +2.47 mL/min/1.73m²/year (p<0.001) through Month 30.
- Sustained UACR reduction of 13.7% (p=0.026) through Month 30.
- Acute eGFR dip was 8.5±0.48 mL/min/1.73 m2 (95% CI: 7.57, 9.44).
- Larger eGFR dips associated with 58% lower risk of death or CV hospitalization (HR: 0.42; P=0.006).
Price Impact
More from BBIO